These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase. Zhou Z, Madrid M, Madura JD. Proteins; 2002 Dec 01; 49(4):529-42. PubMed ID: 12402361 [Abstract] [Full Text] [Related]
5. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase. Carlsson J, Boukharta L, Aqvist J. J Med Chem; 2008 May 08; 51(9):2648-56. PubMed ID: 18410085 [Abstract] [Full Text] [Related]
6. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. Rodríguez-Barrios F, Gago F. J Am Chem Soc; 2004 Dec 01; 126(47):15386-7. PubMed ID: 15563158 [Abstract] [Full Text] [Related]
8. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK. FEBS J; 2006 Aug 01; 273(16):3850-60. PubMed ID: 16911530 [Abstract] [Full Text] [Related]
9. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld D, Kennedy-Smith JJ, Mirzadegan T, Roetz R, Smith M, Sperry S, Suh JM, Wu J, Tsing S, Villaseñor AG, Paul A, Su G, Heilek G, Hang JQ, Zhou AS, Jernelius JA, Zhang FJ, Klumpp K. J Med Chem; 2008 Dec 11; 51(23):7449-58. PubMed ID: 19007201 [Abstract] [Full Text] [Related]
10. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Das K, Lewi PJ, Hughes SH, Arnold E. Prog Biophys Mol Biol; 2005 Jun 11; 88(2):209-31. PubMed ID: 15572156 [Abstract] [Full Text] [Related]
12. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS. Zhou Z, Madura JD. Proteins; 2004 Nov 15; 57(3):493-503. PubMed ID: 15382241 [Abstract] [Full Text] [Related]
13. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. Hopkins AL, Ren J, Milton J, Hazen RJ, Chan JH, Stuart DI, Stammers DK. J Med Chem; 2004 Nov 18; 47(24):5912-22. PubMed ID: 15537346 [Abstract] [Full Text] [Related]
16. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors. Ribone SR, Quevedo MA, Madrid M, Briñón MC. J Chem Inf Model; 2011 Jan 24; 51(1):130-8. PubMed ID: 21133347 [Abstract] [Full Text] [Related]